Unjoni Ewropea - Malti - EMA (European Medicines Agency)

recordati rare diseases - mercaptamine bitartrate - Ċistinosi - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - cystagon huwa indikat għat-trattament ta 'ċistinosi nefropatika ppruvata. cysteamine jnaqqas l-akkumulazzjoni taċ-ċistina f'xi ċelluli (e. lewkoċiti, iċ-ċelloli tal-muskoli u l-fwied) tal-pazjenti nephropathic cystinosis u, meta t-trattament jibda kmieni, huwa dewmien l-iżvilupp tal-falliment renali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

elanco gmbh - benazepril hydrochloride, pimobendan - inibituri ace, kombinazzjonijiet - klieb - għall-kura ta 'insuffiċjenza tal-qalb konġestiva minħabba insuffiċjenza ta' valv atrijoventrikulari jew kardjomijopatija dilwita fil-klieb.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 u 5. 1 għad-data disponibbli dwar kombinazzjonijiet differenti).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ratiopharm gmbh - memantina idrokloridu - marda ta 'alzheimer - psychoanaleptics, - trattament ta 'pazjenti b'mard ta' alzheimer moderat għal sever.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ceva santé animale - virus attenwat tal-vaċċin kontra l-idrofobija ħajjin, strain spbn gasgas - immunoloġiċi għall-canidae, vaċċini virali Ħajjin - red foxes (vulpes vulpes); raccoon dogs (nyctereutes procyonoides) - għall-immunizzazzjoni attiva ta 'volpijiet u klieb tal-rakkun kontra r-rabbja biex jipprevjenu l-infezzjoni u l-mortalità.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

correvio - vernakalant hydrochloride - fibrilazzjoni atrijali - terapija kardijaka - konverżjoni mgħaġġla tal-bidu reċenti fibrillazzjoni atrijali għal sinus rhythm fl-adulti:għall-non-kirurġija il-pazjenti: fibrillazzjoni atrijali .

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

virbac s.a. - clomipramine hydrochloride - psikoanaleptiċi - klieb - as an aid in the treatment of separation related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.